Clerk of the House of Representatives
Legislative Resource Center
135 Cannon Building
Washington, DC 20515
http://lobbyingdisclosure.house.gov 		Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510
http://www.senate.gov/lobby
LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Organization/Lobbying Firm Self Employed Individual
College of American Pathologists

2. Address

Address1
1001 G Street, NW
 Address2
​Suite 425W
City
WASHINGTON
 State
DC
 Zip Code
20001
 Country
USA

3. Principal place of business (if different than line 2)

City
​
State
​
Zip Code
​
Country
​
4a. Contact Name b. Telephone Number c. E-mail
​Mr.
​Michael Giuliani
​2023547103
​nwillia@cap.org
5. Senate ID#
​9897-12
7. Client Name Self Check if client is a state or local government or instrumentality
​College of American Pathologists
6. House ID#
​308370000
TYPE OF REPORT 8. Year
​2025
 Q1 (1/1 - 3/31) Q2 (4/1 - 6/30) Q3 (7/1 - 9/30) Q4 (10/1 - 12/31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report Termination Date
​
11. No Lobbying Issue Activity
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13
12. Lobbying 13. Organizations
INCOME relating to lobbying activities for this reporting period was: EXPENSE relating to lobbying activities for this reporting period were:
Less than $5,000
Less than $5,000
$5,000 or more $
​
$5,000 or more $
​154,425.00
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options.
Method A. Reporting amounts using LDA definitions only

Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Signature
Digitally Signed By: Michael Giuliani
 Date
1/20/2026 2:47:04 PM

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

H.R. 1, the One Big, Beautiful Bill Act
Improving seniors' timely access to care act (S. 1816 / H.R. 3514)
Genomic Data Protection Act
Tariffs
S. 998, Medical Supply Chain Resiliency Act
PAMA reform
S 1399, the Health Tech Investment Act
H.R. 3580, the Oversight of Medicare Billing Code Cost Act
S. 1916 - Protect Genetic information after bankruptcy
S 1830 - HHS has no authority to regulate the practice of medicine
LCD legislation
HR2389/S1302 - Resident Physician Shortage Reduction Act
S2333 - Public Health Workforce Loan Repayment Act
Health Workforce Resilience Act
S665/HR 4942 Conrad 30 and Physician Access Reauthorization Act
CLIA Waiver
CURES 2.0
To prevent across-the-board direct spending cuts
HR 5392, the Timely Access to Coverage Decisions Act of 2023
Remote digital telepathology
HR 977 - legislation that would repeal provisions prohibiting self-referrals to new or expanded POHs.
HR 3248 - Diagnostic Lab Testing Transparency Act
HR 4527 - HEALTH DATA Act
Primary Care and Health Workforce Expansion Act
Gene Therapy
PREVAIL
HR 6371 - budget neutrality bill
HR 2369 - VALID Act
FDA final rule on LDTs
Pandemic All-Hazards Preparedness Act
H.R.9747, the Continuing Appropriations and Extensions Act, 2025
S. 1546/H.R. 3152 The Patent Eligibility Restoration Act
H.R. 6025/S. 3211 - Healthcare Workforce Resilience Act
Cures 2.1
S. 4935, Physician Fee Stabilization Act
Medical Lab Personnel Shortage Relief Act

S. 709/H.R. 1585 - Conrad State 30 and Physician Access Reauthorization Act
S. 1380 - SPARC Act
S. 942/H.R. 2028 - REDI Act
H.R. 879 - Medicare Patient Access and Practice Stabilization Act of 2025
H.R. 1463 - To prohibit the use of Federal funds to implement, administer, or enforce a final rule of the Food and Drug Administration relating to "Medical Devices; Laboratory Developed Tests", and for other purposes.
H.R. 1968 - Continuing Resolution
H.R. 1201 - Doctors in our Borders Act
Issues relating to regulation of laboratory diagnostics
Patent Eligibility Restoration Act
CDC Division of Cancer Prevention and Control and cancer registries appropriations
S. 2439 and H.R. 4731, Resident Physician Shortage Reduction Act
H.R.5371 - Continuing Appropriations and Extensions Act, 2026
HR 3164 - Ensuring Community Access to Pharmacy Services Act (ECAPS)
S 2800 - Pharmacy and Medically Underserved Areas Enhancement Act
S 2420 / H.R. 4710 - No Surprises Act Enforcement Act
S 2793 - Ensuring Access to Essential Providers Act of 2025
H.R. 5582 / S 2355 - Patients Deserve Price Tags Act
Issues related to tariffs
Issues related to public health

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Michael
Giuliani
​
​
Darren
Fenwick
​
​
Michael
Hurlbut
​
​
Hannah
Burriss
​
​
Kristin
McDonald
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

FY 2026 Appropriations
Student VISA issues
Price Tags / Transparency Legislation
CDC funding
NIH Funding
CLIAC reinstatement
Issues relating to surprise medical bills
Pandemic and All-Hazards Preparedness Act (PAHPA) Reauthorization
Advocating for relief from cuts to evaluation and management codes within Medicare
Issues relating to the debt limit
Issues relating to site-neutral payments
Issue relating to artificial intelligence
Issues relating to combatting fentanyl crisis
Issues relating to Medicare coverage pathways
Researching Long Covid
Fees paid on electronically submitting to insurers
Issues relating to the Clinical Laboratory Fee Schedule
Issues relating to forensic pathologist loan repayment
Funding for the CDC AMD program
Funding for lab test harmonization
Issues surrounding Health Data Privacy
Issues surrounding the Change Healthcare Cyber Attack
Medicare payment reform
S.4338 - Pay PCPs Act of 2024
Challenges facing independent medicine
PTAC Reform
Issues relating to blood donations
Issues relating to the local coverage determination process
Issues relating to GME
Issues relating to laboratory accreditation procedures of IVF centers
Issues relating to site neutral payment reform
Issues relating to Medicaid funding
S. 2761 and H.R. 5269, the RESULTS Act
Issues related to cancer
Issues related to the Medicare Access and CHIP Reauthorization Act of 2015

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name Last Name Suffix Covered Official Position (if applicable) New
Michael
Giuliani
​
​
Darren
Fenwick
​
​
Michael
Hurlbut
​
​
Hannah
Burriss
​
​
Kristin
McDonald
​
​

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

​

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

Address
​
City
​
State
​
Zip Code
​
Country
​

21. Client new principal place of business (if different than line 20)

City
​
State
​
Zip Code
​
Country
​

22. New General description of client’s business or activities

​

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

First Name
Last Name
Suffix
First Name
Last Name
Suffix
1
​Hannah
​Burriss
​
3
​
​
​
2
​
​
​
4
​
​
​

ISSUE UPDATE

24. General lobbying issue that no longer pertains

​
​
​
​
​
​
​
​
​

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

Name Address Principal Place of Business
(city and state or country)
Street Address
City State/Province Zip Country
City
State Country

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

1 2 3

FOREIGN ENTITIES

27. Add the following foreign entities:

Name Address Principal place of business
(city and state or country) 		Amount of contribution for lobbying activities Ownership percentage in client
Street Address
City State/Province Country
City
State Country
%

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

1 3 5
2 4 6

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?

Lobbyist Name Description of Offense(s)